Inflammation in peripheral arterial disease (PAD)

Current Pharmaceutical Design

Volumn 18, Issue 28, 2012, Pages 4350-4357

  Signorelli, Salvatore Santo ^a,b   Anzaldi, Massimiliano ^a   Fiore, Valerio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Garibaldi Central Hospital   (Italy)

Author keywords

Biomarkers; Medical therapy; Peripheral arterial disease; Phlogosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; METALLOPROTEINASE; SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CRITICAL LIMB ISCHEMIA; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

AGE FACTORS; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE;

EID: 84866363565     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802481273     Document Type: Review

References (107)

1. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003 Apr 28; 163(8): 884-892.
2. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997; 2(3): 221-226.
3. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch HJ. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004 Jan; 172(1): 95-105.
4. Brevetti G, Schiano V, Verdoliva S, Silvestro A, Sirico G, De Maio J, Lanero S, Chiariello M.Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown). 2006 Aug; 7(8): 608-613.
5. Signorelli S, Anzaldi M, Fiore V, Catanzaro S, Simili M, Torrisi B, Neri S. Study on unrecognized peripheral arterial disease (PAD) by ankle/brachial index and arterial co-morbidity in Catania (Sicily, Italy) Angiology 2010. Angiology. 2010; 61: 524-529.
6. Cimminiello C: PAD. Epidemiology and pathophysiology. Thromb Res.106: V295-V301, 2002.
7. Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G, Haberl RL, Allenberg JR, Dasch B, Trampisch HJ. Association of low ankle brachial index with high mortality in primary care. Eur Heart J. 2006 Jul; 27(14): 1743-1749. Epub 2006 Jun 16.
8. Doobay AV, Anand SS. Sensitivity and specificity of the anklebrachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005 Jul; 25(7): 1463-1469. Epub 2005 May 5.
9. Holland-Letz T, Endres HG, Bleckerman S. Reproducibility of the ankle-brachial index as assessed by vascular experts, family physicians and nurses. Vasc Med 2008; 12: 105-1012
10. Rosamnod M, Flegal NK, Furie K et al. Heart disease and stroke: statistics 2008 updtae: a report from the American heart Association Statistics Committee and Stroke Statistics Subcommitee. Circulation 2008; 117: e25-e146
11. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW. REACH Registry Investigators The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 Apr; 151(4): 786.e1-e10.
12. Hackam DG, Tan MK, Lin PJ, Mehta PG, Jaffer S, Kates M, Oh M, Grima EA, Langer A, Goodman SG; Vascular Protection Registry; Guideline Oriented Approach in Lipid Lowering Registry Investigators Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. J Vasc Surg. 2006 Oct; 44(4): 776-781. Epub 2006 Aug 23.
13. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007; 33 Suppl 1: S1-S75.
14. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 Sep 19; 286(11): 1317-1324.
15. Hirsch AT, Hiatt WR; PARTNERS Steering Committee. PAD awareness, risk, and treatment: new resources for survival-the USA PARTNERS program. Vasc Med. 2001; 6(3 Suppl): 9-12.
16. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J, Michon P, Herrmann MA, Priollet P. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg. 2006 Aug; 44(2): 314-318.
17. Jenny NS, Yanez ND, Pasty BM, Kuller LH, Hirsh CH, Tracy RP. Inflammation biomarkers and near-term death in older man. Am J Epidemiol 2007; 165: 445-451
18. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 138: S419-S420, 1999.
19. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(suppl 2): S9-S12.
20. Murabito JM, Keyes MJ, Guo CY, Keaney JF Jr, Vasan RS, D'Agostino RB Sr, Benjamin EJ. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis. 2009 Apr; 203(2): 509-514.
21. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer CD. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest. 2009 Jun; 39(6): 437-444. Epub 2009 Apr 9.
22. Lin CW, Hsu LA, Chen CC, Yeh JT, Sun JH, Lin CH, Chen ST, Hsu BR, Huang YY. C-reactive protein as an outcome predictor for percutaneous transluminal angioplasty in diabetic patients with peripheral arterial disease and infected foot ulcers. Diabetes Res Clin Pract. 2010 Nov; 90(2): 167-172. Epub 2010 Sep 6.
23. Nishida H, Horio T, Suzuki Y, Iwashima Y, Tokudome T, Yoshihara F, Nakamura S, Kawano Y. Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine. 2011 Mar; 53(3): 342-346 Epub 2010 Dec 28.]
24. Flex A, Gaetani E, Angelini F, Sabusco A, Chillà C, Straface G, Biscetti F, Pola P, Castellot JJ Jr, Pola R Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med. 2007 Jul; 262(1): 124-130
25. Ramakrishina PC Chaparala, Orsi NM, Lindsey N, Girn RS, Homer-Vanniasinkan S. LInflammatory profiling of peripheral arterial disease. Ann Vasc Surg 2009; 20(2)172-178
26. Thomas JC, Vohra RS, Beer S, Bhatti K, Ponnambalam S, Homer-Vanniasinkam S. Biomarkers in peripheral arterial disease. Trends Cardiovasc Med. 2009 Jul; 19(5): 147-151.
27. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005 Nov 15; 96(10): 1374-1378.
28. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005 Feb; 29(2): 171-176
29. Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet. 1990 Mar 10; 335(8689): 555-557.
30. Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia. Therapie. 1991 Jul-Aug; 46(4): 319-322.
31. Lessiani G, Vazzana N, Cuccurullo C, Di Michele D, Laurora G, Sgrò G, Di Ruscio P, Simeone E, Di Iorio P, Lattanzio S, Liani R, Ferrante E, Davì G. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Thromb Haemost. 2011 Feb 1; 105(2): 321-328.
32. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology. 2011 Jan; 62(1): 15-17.
33. Shalhoub J, Davies AH, Franklin IJ. Cilostazol may improve outcome in critical limb ischemia. Int Angiol. 2009 Oct; 28(5): 363-366.
34. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg ESigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg E., Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg E. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. Vasc Surg. 2007 Jun; 45(6): 1185-1891.
35. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, Djoussé L, Eckfeldt JH; Investigators of the NHBLI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001 Jul 15; 88(2): 112-127
36. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251-262,
37. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002; 91: 852-859,.
38. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994.; 94: 2493-2503,
39. Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, Petrina M, Nicotra GS, Indelicato M, Navolanic PM, Pennisi G, Mazzarino MC. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med Feb; 10(1): 1-6. 2005
40. Ley K. The role of selectins in inflammation and disease. Trend in Mol Med 2003; 9 (5): 263-268
41. Boulbou MS, Koukoulis GN, Vasiou KG, Petinaki EA, Gourgoulianis KI, Fezoulidis IB. Increased soluble E-selectin levels in type 2 diabetic patients with peripheral arterial disease. Int Angiol. 2004 Mar; 23(1): 18-24.
42. Signorelli SS, Mazzarino MC, Di Pino L, et al: High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 8: 15-19, 2003.
43. Merten M, Thaigarain P. P-selectin in arterial trombosis. Z.Kardiol 2004; 53(11): 855-863
44. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, White DB, Commerota AJ. Effect of antiplateletagents clopridrogel, aspirn and cilastazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2008; 95(6): 738-743.
45. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-265
46. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011 Jan; 269(1): 16-28
47. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103(1 Pt 1): 11-24.
48. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(suppl 2): S9-S12.
49. Fiotti N, Giansante C, Ponte E et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145: 51-60.
50. McDermott MM, Guralnik JM, Corsi A et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 2005; 150: 276-281
51. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-983.
52. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-265.
53. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204.
54. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010 Aug 27; 33(2): 153-165
55. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453-463.
56. Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006; 212: 114-130.
57. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat of activation is essential for interleukin-4 induction of Pselectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1421-1429.
58. Depalma RG, hayes VW, Chow BK, Shamayevu G, May PE, Zackarski LR. Ferritin lebels, inflammatory biomarkers, and mortality in peripheral arterial disease: A substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) trial. J Vasc Surg 2010; 51: 1498-1503.
59. Szodoray P, Timar O, Veres K et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines -immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64: 336-344.
60. Hellingman AA, Zwaginga JJ, van Beem RT; TeRM/Smart Mix Consortium, Hamming JF, Fibbe WE, Quax PH, Geutskens SB. Tcell-pre-stimulated monocytes promote neovascularisation in a murine hind limb ischaemia model. Eur J Vasc Endovasc Surg. 2011 Mar; 41(3): 418-428
61. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci. 2011 Jan 1; 16: 1663-1674.
62. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007 Feb; 28(3): 354-362
63. Nylaende M, Kroese A, Stranden E, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21-28.
64. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G, Marchese G, Costa MP, Digrandi D, Celotta G, Virgilio V. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003; 8: 15-19
65. McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Tao H, Ridker PM, Criqui MH. Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. Am J Cardiol. 2011 May 1; 107(9): 1392-1398
66. Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993. 53.
67. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-626.
68. Haddy N, Sass C, Droesch S et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-283.
69. Allison MA, Criqui MH, McClelland RL et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190-1997
70. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59(2): 211-215, 2006
71. Burzotta F, Iacoviello L, Di Castelnuovo A, et al: Relation of the - 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 1588: 1125-1128, 2001.
72. Giacconi R, Cipriano C, Albanese F, et al: The -174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol 39: 621-628, 2004
73. Greisenegger S, Endler G, Haering D, Schillinger M, Lang W, Lalouschek W and Mannhalter C: The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. Thromb Res 110: 181-186, 2003.
74. Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283, 2000;
75. Chapman CM, Beilby JP, Humphries SE, Palmer LJ, Thompson PL and Hung J: Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J 24: 1494-1499, 2003.
76. Stoica AL, Stoica E, Constantinescu I, Uscatescu V, Ginghina C. Interleukin-6 and interleukin-10 gene polymorphism, endothelial dysfunction, and postoperative prognosis in patients with peripheral arterial disease. J Vasc Surg. 2010 Jul; 52(1): 103-109.
77. Libra M, Signorelli SS, Bevelacqua Y, et al: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59: 211-215, 2006.
78. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med. 2009 Aug; 266(2): 141-53
79. Damas JK, Waehre T, Yndestad A et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003; 107: 2670-2676.
80. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA. Interleukin 8 and cardiovascular disease. Cardiovasc Res. 2009 Dec 1; 84(3): 353-360.
81. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptordeficient mice. J Clin Invest 1998; 101: 353-363.
82. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420-426.
83. Kirk G, Hickman P, McLaren M, Stonebridge PA, Belch JJ. Interleukin- 8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg 1999; 18: 434-438
84. Marino F, Guasti L, Tozzi M, Consuelo Maio R, Castiglioni L, Rasini E, Schembri L, Maroni L, Legnaro M, De Leo A, Piffaretti G, Castelli P, Venco A, Lecchini S, Cosentino M. Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2009 Dec; 54(6): 520-525.
85. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010 Oct; 21(5): 331-344
86. Namiki M, Kawashima S, Yamashita T et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-29.
87. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin- 10 in atherosclerosis. Circ Res 1999; 85: e17-e24
88. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-616.
89. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Münzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S; Athero Gene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005 Aug 2; 112(5): 643-650.
90. Anguera I, Miranda-Guardiola F, Bosch X et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811-817.
91. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-749.
92. Heeschen C, Dimmeler S, Hamm CW et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-2114.
93. Blanco E, Moñux G, Mas A, Serrano FJ, de la Concha EG, Urcelay E. Role of IL-10 promoter polymorphisms in the development of severe aorto-iliac occlusive disease. Hum Immunol. 2008 Oct; 69(10): 651-654.
94. Stoica AL, Stoica E, Constantinescu I, Uscatescu V, Ginghina C. Interleukin-6 and interleukin-10 gene polymorphism, endothelial dysfunction, and postoperative prognosis in patients with peripheral arterial disease. J Vasc Surg. 2010 Jul; 52(1): 103-109.
95. Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine. 2010 Oct-Nov; 52(1-2): 102-107.
96. Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin- 12 function by protein vaccination attenuates atherosclerosis. Circulation 2005; 112: 1054-1062.
97. Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-2138.
98. Zhang X, Niessner A, Nakajima T et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98: 524-531.
99. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol. 2011 Mar; 89(3): 383-392.
100. Mallat Z, Corbaz A, Scoazec A et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-E45.
101. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-1603
102. Vlachopoulos C, Ioakeimidis N, Aznaouridis K, Bratsas A, Baou K, Xaplanteris P, Lazaros G, Stefanadis C. Association of interleukin-18 levels with global arterial function and early structural changes in men without cardiovascular disease. Am J Hypertens. 2010 Apr; 23(4): 351-357.
103. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010 May; 85: 27-39.
104. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
105. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501-507.
106. Barani J, Nilsson JA, Mattiasson I, Lindblad B, Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 2005; 42: 75-80.
107. Stehouwer CDA, Clement D, Davidson C, Diehm C, Elte JW, Lambert M, Dereni D,. Peripheral arterial disease: a growing problems for the internist. Eur J of Int Med 2009; 20: 132-138.